Stopping GLP-1 Weight-Loss Drugs Linked to Double the Risk of Heart Attack, Stroke or Death

The findings, shared by the BMJ, point to a potentially serious consequence of discontinuing a class of drugs that has become widely prescribed for both type 2 diabetes and weight loss. GLP-1 receptor agonists — medicines that mimic a gut hormone to help control blood sugar and reduce appetite — include drugs such as semaglutide and liraglutide, sold under brand names including Ozempic and Victoza.

According to the study, stopping GLP-1 treatment was linked to twice the combined risk of cardiovascular events — heart attacks, strokes, or death — for some people living with type 2 diabetes.

The research adds to a growing body of evidence that GLP-1 drugs do more than manage blood sugar. Trials have already shown cardiovascular benefits from staying on these medicines, and this study suggests that coming off them may reverse some of that protection.

People don’t always stop these medicines by choice. Supply shortages, cost pressures, or side effects can all lead to treatment gaps — which makes the findings relevant to patients and prescribers alike.

The NHS does prescribe GLP-1 medicines for type 2 diabetes and, in some cases, for weight management, though eligibility criteria apply. Anyone concerned about their current treatment — or thinking about stopping — should speak to their GP or diabetes care team before making any changes. Do not stop prescribed medication without medical advice.

Key information

• Do not stop GLP-1 medication without speaking to your GP or diabetes nurse first
• Call NHS 111 if you have concerns about your medication and cannot reach your GP
• In an emergency — chest pain, sudden weakness, or difficulty speaking — call 999 immediately